Followers | 822 |
Posts | 163138 |
Boards Moderated | 6 |
Alias Born | 09/23/2009 |
Friday, May 20, 2016 8:54:25 AM
KELOWNA, BC / ACCESSWIRE / May 20, 2016 / Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company") is very pleased to announced it has entered into the definitive agreement first announced in a Letter of Intent dated March 22, 2016, to license its patent pending technology for the purpose of entering the U.S. regulated medical and adult use cannabis edibles marketplace. This agreement marks a major milestone for the Company: the first contracted, predictable and significant revenue streams to be achieved as a direct result of Lexaria's technological advantages in the marketplace.
Under the terms of the agreement and as earlier announced, the Licensee will pay a minimum of US$122,000 in pre-defined staged payments to Lexaria over the initial two-year term, which will commence in the state of Colorado. The agreement contemplates significant opportunities to expand, both in scope of products offered in Colorado as well as to other states such as California, Washington, and Oregon. As per the Agreement, if the Licensee were to introduce certain product lines utilizing Lexaria's technology in each of the four states contemplated, for example, then Lexaria could expect to receive a maximum of $1,064,000 over approx 3 ½ years, and the Licensee would enjoy semi-exclusivity to introduce its quality products in each of those states.
The Licensee is preparing its outstanding products for the marketplace at this time, and Lexaria is further protecting competitive advantages by seeking to maintain the confidentiality of certain strategic information from the industry. Lexaria is not itself producing any products under the agreement, and instead is making its technology available to the Licensee and state-licensed partners.
Lexaria continues discussions with other companies also interested in licensing Lexaria's absorption technology that provides for improved food consumption experiences and performance. Lexaria's technology provides significant competitive advantages to its licensed partners, such as flavour enhancement without the use of large amounts of sweeteners; and of course, higher bioavailability both by total quantity of bioactive substance that is absorbed as well as enhancing how quickly this occurs. These advantages lead to higher quality experiences for consumers while delivering competitive advantages to companies utilizing the technology.
"We could not be more pleased to see our technology being utilized within new sectors," said John Docherty, President of Lexaria. "Our technology enables superior experiences for customers as evidenced in in vitro testing conducted to date, and our partner is making a strong commitment to provide their customers with the very best that cutting edge science and technology can provide."
Attorneys with expertise in intellectual property law and cannabis-specific practices have come together to create one of the first technology licensing agreements of its kind with application to cannabinoids. Lexaria Bioscience has received requests from companies located in North America, Europe, and the Caribbean related to applications for its technology for enhancing the delivery of other payload molecules including but not limited to cannabinoids and is actively evaluating other technology licensing opportunities which it will disclose in due course.
"We've been transparent with stakeholders as to the validity and application of our encapsulation technology and that we would leverage it with licensed partners for mutual benefit," said Chris Bunka, CEO of Lexaria. "There is great complexity in defining and constructing precise and lasting agreements and these require thoughtful consideration. Our goal remains to place our technology in food products across America and internationally, not only within the cannabinoid food sector, but also with vitamins, NSAIDs and more, creating entirely new and unprecedented product categories."
Lexaria's unique patent pending technology allows for more efficient and effective absorption of certain molecules such as vitamins and cannabinoids, while simultaneously masking and at times even eliminating inherent strong flavours and/or odors typical of those molecules. Lexaria's technology is extremely cost effective to implement and applicable to the widest imaginable spectrum of foods including but not limited to chocolates, candies, coffee, tea, a wide variety of other beverages, protein bars, cookies, pastas, entrees, breads, and much more.
About Lexaria
Lexaria Bioscience Corp. is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies. Lexaria's technology enables higher bioavailability rates for CBD; THC; NSAIDs; Nicotine and other molecules than is possible without lipophilic enhancement technology. This can allow for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. Lexaria hopes to reduce other common but less healthy ingestion methods such as smoking as it embraces the benefits of public health. www.lexariaenergy.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424
Recent LEXX News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/06/2024 11:00:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 07:28:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:30:59 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/16/2024 08:47:26 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:20:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 06:51:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 07:12:07 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/24/2024 06:33:08 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/18/2024 07:38:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 10:11:16 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs • InvestorsHub NewsWire • 01/08/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:07:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/30/2023 09:14:31 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/20/2023 10:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 05:13:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 05:45:34 PM
- Get Ready for Next Generation of Diabetes, Weight-Management Drugs • InvestorsHub NewsWire • 11/01/2023 12:45:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM